SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
December 1, 2019
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
6836 Bee Cave Road
Building III, Suite 200
Austin, TX 78746
(Address of principal executive offices, including zip code)
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
|Common Stock, par value $0.001 per share||SVRA||The Nasdaq Global Select Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Departure of Director
On December 1, 2019, Yuri Pikover, a member of the Board of Directors (the Board) of Savara Inc. (the Company), resigned from the Board effective immediately. Mr. Pikover served as a member of the Audit Committee of the Board and as the chair of the Nominating & Governance Committee of the Board. Mr. Pikovers decision to resign was not related to a disagreement with the Company over any of its operations, policies or practices.
Election of Director
On December 3, 2019, the Board elected An van Es-Johansson, M.D. to the Board, effective immediately, and appointed Dr. van Es-Johansson to serve as a member of the Compensation Committee of the Board. The Company plans to enter into an indemnification agreement with Dr. van Es-Johansson in the standard form used for the Companys other Board members. Dr. van Es-Johansson will receive cash and equity compensation for her service on the Board and Board committee(s) under the Companys compensation program for other non-employee directors.
There are no transactions between Dr. van Es-Johansson and the Company that would be reportable under Item 404(a) of Regulation S-K. Dr. van Es-Johansson was not selected as a director pursuant to any arrangement or understanding between her and any other person.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: December 3, 2019||SAVARA INC. |
a Delaware corporation
Chief Financial Officer